Safe and active advanced T cell therapies

We apply our broad array of T cell programing technologies and capabilities to engineer precisely targeted controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eradicate these cancer cells.

CAR T cell therapies

We use Chimeric Antigen Receptors (CARs) to reprogram our T cell product candidates. These receptors combine the tumor recognition domain of an antibody with the activation and costimulatory domains from the t cell receptor to rearm a patient’s T cells to recognize and kill their cancer cells.

Find out more

Advanced cell programing technology

Autolus is applying its extensive cell programing capability to develop a pipeline of precise, controlled and highly active products.

Read more


We manufacture our product candidates and commercial supply in the UK.

Learn more

Latest Abstracts & Publications

See all
American Society of Hematology Annual Meeting
December 13 2021

Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

American Society of Hematology Annual Meeting
December 12 2021

Industrialization of an Academic Miltenyi Prodigy-Based CAR T process

American Society of Hematology Annual Meeting
December 11 2021

A high sensitivity aCD22 CAR combined with aCD19 CAR to generate dual targeting CAR T cells for the treatment of r/r B-ALL